Latest in News & Research

LAUNCH ALERT: FDA Approves IDP-126 Gel for Acne Vulgaris

The once-daily triple-combination topical acne treatment is approved for use in patients 12 years and older

By Dermsquared Editorial Team | | October 25, 2023

Social Stigma Associated With Adult Facial Acne

Faces with acne rated as less attractive, trustworthy, confident, successful, dominant, and happy

By Lori Solomon (HealthDay News) | | October 20, 2023

LAUNCH ALERT: Bimzelx Approved For Moderate-to-Severe Plaque psoriasis

The groundbreaking injectable biologic agent demonstrates unprecedented efficacy in the treatment of psoriasis.

By Dermsquared Editorial Team | | October 20, 2023

FDA Approves Nivolumab as Adjuvant Treatment for Melanoma

Approval granted for patients aged 12 years and older with stage IIB/C disease

By Lori Solomon (HealthDay News) | | October 18, 2023

Is Nonmelanoma Skin Cancer Causing More Deaths Than Melanoma?

Global melanoma incidence was 324,635 in 2020, resulting in 57,043 deaths, while 63,731 NMSC deaths were reported

By Dermsquared Editorial Team | | October 18, 2023

Is Extensive Perineural Invasion Best Prognostic Measure for Cutaneous Squamous Cell Carcinoma?

Perineural invasion of five or more nerves independently linked to local recurrence, disease-specific death, any poor outcome

By Dermsquared Editorial Team | | October 18, 2023

Half of Patients With Newly Diagnosed Vitiligo Do Not Receive Treatment

Proportion receiving treatment within 12 months higher with more severe disease

By Lori Solomon (HealthDay News) | | October 17, 2023

How Does Lesion Visibility Affect Melanoma Prognosis?

Patients with nonvisible lesions more likely to have T3 or T4 tumors, positive lymph nodes, higher-risk stage

By Dermsquared Editorial Team | | October 11, 2023

Is Autologous Cell Transplant Reliable for Stable Segmental Vitiligo?

Cultivated cells have better results than noncultivated ones; both types pigment 80 percent or more where needed

By Dermsquared Editorial Team | | October 11, 2023

Autoimmune, Autoinflammatory Connective Tissue Disorders Increased After COVID-19

Risks associated with COVID-19 severity

By Elana Gotkine (HealthDay News) | | October 10, 2023

Risankizumab Treatment Beneficial in Real-World Psoriasis Cohort

High levels of clear and clear/almost clear skin, significant reductions in psoriasis symptoms reported at one year after initiation

By Dermsquared Editorial Team | | October 04, 2023

Black Race Linked to Worse Survival in Kaposi Sarcoma

Survival benefit seen for Spanish/Hispanic ethnicity, private insurance, residence in areas of high educational attainment

By Dermsquared Editorial Team | | October 04, 2023

Sexual, Gender Minorities With Chronic Skin Diseases More Likely to Face Barriers to Care

Cost and noncost barriers more likely for sexual and gender-minority patients with chronic inflammatory skin diseases

By Elana Gotkine (HealthDay News) | | October 03, 2023

Children With Eczema More Likely to Have Allergic Contact Dermatitis

Children with atopic dermatitis more likely to have more than one positive patch test result

By Elana Gotkine (HealthDay News) | | October 02, 2023

Vitiligo and Associated Comorbidities: A Review

The pigmentary disorder is linked to a host of autoimmune disorders, ocular and auditory abnormalities, and dermatologic conditions

By Jenny She [1], Stephen Moore [1], Harrison P. Nguyen, MD, MBA, MPH [1,2] | | October 02, 2023

Does Adding Optical Coherence Tomography Increase Detection of Recurrent, Residual BCC?

Area under curve 0.98 for clinical and dermatoscopic examination combined with OCT and 0.77 for clinical and dermatoscopic examination alone

By Dermsquared Editorial Team | | September 27, 2023

Itching, Sleep Disturbance Impact QoL in Prurigo Nodularis

All patients with PN reported itch, pain associated with PN, bleeding or scabbing, and having dry skin

By Dermsquared Editorial Team | | September 27, 2023

Reduced Mortality Risk Seen for Patients With Vitiligo

Lower all-cause and cause-specific mortality seen, including from infectious diseases, oncologic diseases, endocrine diseases

By Elana Gotkine (HealthDay News) | | September 26, 2023

Both Ciclosporin, Methotrexate Effective for Severe Eczema in Children

Greater improvement seen in disease severity by 12 weeks with ciclosporin, but MTX was superior by 60 weeks

By Elana Gotkine (HealthDay News) | | September 26, 2023

Study Looks at Treatment Patterns for Alopecia Areata

47.2 percent received no treatment on day of diagnosis; by one year, 71.8 percent were not receiving treatment

By Elana Gotkine (HealthDay News) | | September 20, 2023

Coronary Microvascular Dysfunction ID'd in 31.5 Percent With Psoriasis

Independent association with CMD seen for higher PASI, longer disease duration, psoriatic arthritis, hypertension

By Elana Gotkine (HealthDay News) | | September 20, 2023

Combo Treatments Efficacious for Generalized-Type Vitiligo

No difference seen in efficacy for NB-UVB treatment combined with tacrolimus 0.1 percent or calcipotriol/betamethasone dipropionate

By HealthDay News | | September 20, 2023

Somatosensory Profiles Characterized in Hidradenitis Suppurativa

HS lesions insensitive to innocuous cold and warmth, noxious heat, and light touch compared with healthy pain-free controls

By Dermsquared Editorial Team | | September 20, 2023

24 of 1274

Headline from the Week of August 17 - 23, 2026

Peripheral Globules, Related Lesion Dynamics Predict Outcomes in Melanocytic Nevi

By Dermsquared Editorial Team | | August 18, 2026

Upadacitinib Has Positive Benefit-Risk Profile for Severe Alopecia Areata

By Dermsquared Editorial Team | | August 18, 2026